Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOX PARK: Botulinum Toxin for Refractory Resting Tremor in Parkinson's Disease
NCT07822893Phase 3Not yet recruiting
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Dec 2026
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
A Phase 3 trial of botulinum toxin type A in Parkinson's disease (PD), sponsored by Centre hospitalier universitaire de Toulouse. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT07822893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07822893.